Systemic aspirin and systemic vitamin E in senile cataracts: cataract V

Area of Science:

• Ophthalmology
• Pharmacology
• Gerontology

Background:

• Senile cataract is a leading cause of vision impairment in the elderly.
• Current pharmacological interventions for cataract progression are limited.
• Investigating agents like aspirin and vitamin E for potential therapeutic benefits.

Purpose of the Study:

• To prospectively evaluate the efficacy of systemic aspirin and vitamin E in slowing the progression of senile cataracts.
• To assess the impact of these agents on visual acuity and various types of lens opacities.

Main Methods:

• Prospective study involving senile cataract patients.
• Treatment groups received either systemic aspirin or systemic vitamin E.
• Control group received no treatment; outcomes assessed via vision maintenance and opacity progression.

Main Results:

• Vitamin E showed a trend towards reduced posterior subcapsular (PSC) and nuclear opacities but no overall benefit compared to controls.
• Systemic aspirin group demonstrated better vision maintenance and less vision loss.
• Aspirin significantly reduced the mean increase in cortical, nuclear, and PSC opacities, as well as their density.

Conclusions:

• Systemic aspirin appears to be a potential therapeutic agent for slowing cataract progression, warranting further investigation.
• The observed benefits of aspirin on vision and opacity metrics suggest a promising role.
• Larger, double-blind, photodocumented studies are essential to confirm these findings before clinical recommendation.